

Global Blood Cancer Treatments Market Growth 2026-2032

<https://marketpublishers.com/r/GEE76FEA5386EN.html>

Date: July 2026

Pages: 150

Price: US\$ 3,660.00 (Single User License)

ID: GEE76FEA5386EN

Abstracts

The global Blood Cancer Treatments market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.

United States market for Blood Cancer Treatments is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Blood Cancer Treatments is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Blood Cancer Treatments is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Blood Cancer Treatments players cover Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the 'Blood Cancer Treatments Industry Forecast' looks at past sales and reviews total world Blood Cancer Treatments sales in 2025, providing a comprehensive analysis by region and market sector of projected Blood Cancer Treatments sales for 2026 through 2032. With Blood Cancer Treatments sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Blood Cancer Treatments

industry.

This Insight Report provides a comprehensive analysis of the global Blood Cancer Treatments landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Blood Cancer Treatments portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Blood Cancer Treatments market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood Cancer Treatments and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood Cancer Treatments.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood Cancer Treatments market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Segmentation by Application:

Leukemia

lymphoma

Myeloma

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

Key Questions Addressed in this Report

What is the 10-year outlook for the global Blood Cancer Treatments market?

What factors are driving Blood Cancer Treatments market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Blood Cancer Treatments market opportunities vary by end market size?

How does Blood Cancer Treatments break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Blood Cancer Treatments Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Blood Cancer Treatments by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Blood Cancer Treatments by Country/Region, 2021, 2025 & 2032
- 2.2 Blood Cancer Treatments Segment by Type
 - 2.2.1 Chemotherapy
 - 2.2.2 Targeted Therapy
 - 2.2.3 Immunotherapy (Biologic Therapy)
 - 2.2.4 Hormonal Therapy
 - 2.2.5 Others
 - 2.2.6 Blood Cancer Treatments Sales by Type
 - 2.2.6.1 Global Blood Cancer Treatments Sales Market Share by Type (2021-2026)
 - 2.2.6.2 Global Blood Cancer Treatments Revenue and Market Share by Type (2021-2026)
 - 2.2.6.3 Global Blood Cancer Treatments Sale Price by Type (2021-2026)
- 2.3 Blood Cancer Treatments Segment by Application
 - 2.3.1 Leukemia
 - 2.3.2 lymphoma
 - 2.3.3 Myeloma
 - 2.3.4 Others
 - 2.3.5 Blood Cancer Treatments Sales by Application
 - 2.3.5.1 Global Blood Cancer Treatments Sale Market Share by Application

(2021-2026)

2.3.5.2 Global Blood Cancer Treatments Revenue and Market Share by Application

(2021-2026)

2.3.5.3 Global Blood Cancer Treatments Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Blood Cancer Treatments Breakdown Data by Company

3.1.1 Global Blood Cancer Treatments Annual Sales by Company (2021-2026)

3.1.2 Global Blood Cancer Treatments Sales Market Share by Company (2021-2026)

3.2 Global Blood Cancer Treatments Annual Revenue by Company (2021-2026)

3.2.1 Global Blood Cancer Treatments Revenue by Company (2021-2026)

3.2.2 Global Blood Cancer Treatments Revenue Market Share by Company
(2021-2026)

3.3 Global Blood Cancer Treatments Sale Price by Company

3.4 Key Manufacturers Blood Cancer Treatments Producing Area Distribution, Sales
Area, Product Type

3.4.1 Key Manufacturers Blood Cancer Treatments Product Location Distribution

3.4.2 Players Blood Cancer Treatments Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BLOOD CANCER TREATMENTS BY GEOGRAPHIC REGION

4.1 World Historic Blood Cancer Treatments Market Size by Geographic Region
(2021-2026)

4.1.1 Global Blood Cancer Treatments Annual Sales by Geographic Region
(2021-2026)

4.1.2 Global Blood Cancer Treatments Annual Revenue by Geographic Region
(2021-2026)

4.2 World Historic Blood Cancer Treatments Market Size by Country/Region
(2021-2026)

4.2.1 Global Blood Cancer Treatments Annual Sales by Country/Region (2021-2026)
4.2.2 Global Blood Cancer Treatments Annual Revenue by Country/Region
(2021-2026)

- 4.3 Americas Blood Cancer Treatments Sales Growth
- 4.4 APAC Blood Cancer Treatments Sales Growth
- 4.5 Europe Blood Cancer Treatments Sales Growth
- 4.6 Middle East & Africa Blood Cancer Treatments Sales Growth

5 AMERICAS

- 5.1 Americas Blood Cancer Treatments Sales by Country
 - 5.1.1 Americas Blood Cancer Treatments Sales by Country (2021-2026)
 - 5.1.2 Americas Blood Cancer Treatments Revenue by Country (2021-2026)
- 5.2 Americas Blood Cancer Treatments Sales by Type (2021-2026)
- 5.3 Americas Blood Cancer Treatments Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Blood Cancer Treatments Sales by Region
 - 6.1.1 APAC Blood Cancer Treatments Sales by Region (2021-2026)
 - 6.1.2 APAC Blood Cancer Treatments Revenue by Region (2021-2026)
- 6.2 APAC Blood Cancer Treatments Sales by Type (2021-2026)
- 6.3 APAC Blood Cancer Treatments Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Blood Cancer Treatments by Country
 - 7.1.1 Europe Blood Cancer Treatments Sales by Country (2021-2026)
 - 7.1.2 Europe Blood Cancer Treatments Revenue by Country (2021-2026)
- 7.2 Europe Blood Cancer Treatments Sales by Type (2021-2026)
- 7.3 Europe Blood Cancer Treatments Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Blood Cancer Treatments by Country

8.1.1 Middle East & Africa Blood Cancer Treatments Sales by Country (2021-2026)

8.1.2 Middle East & Africa Blood Cancer Treatments Revenue by Country (2021-2026)

8.2 Middle East & Africa Blood Cancer Treatments Sales by Type (2021-2026)

8.3 Middle East & Africa Blood Cancer Treatments Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Blood Cancer Treatments

10.3 Manufacturing Process Analysis of Blood Cancer Treatments

10.4 Industry Chain Structure of Blood Cancer Treatments

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Blood Cancer Treatments Distributors

11.3 Blood Cancer Treatments Customer

12 WORLD FORECAST REVIEW FOR BLOOD CANCER TREATMENTS BY GEOGRAPHIC REGION

12.1 Global Blood Cancer Treatments Market Size Forecast by Region

12.1.1 Global Blood Cancer Treatments Forecast by Region (2027-2032)

12.1.2 Global Blood Cancer Treatments Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Blood Cancer Treatments Forecast by Type (2027-2032)

12.7 Global Blood Cancer Treatments Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Roche

13.1.1 Roche Company Information

13.1.2 Roche Blood Cancer Treatments Product Portfolios and Specifications

13.1.3 Roche Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Roche Main Business Overview

13.1.5 Roche Latest Developments

13.2 Celgene

13.2.1 Celgene Company Information

13.2.2 Celgene Blood Cancer Treatments Product Portfolios and Specifications

13.2.3 Celgene Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Celgene Main Business Overview

13.2.5 Celgene Latest Developments

13.3 Novartis

13.3.1 Novartis Company Information

13.3.2 Novartis Blood Cancer Treatments Product Portfolios and Specifications

13.3.3 Novartis Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Novartis Main Business Overview

13.3.5 Novartis Latest Developments

13.4 Bristol-Myers Squibb

- 13.4.1 Bristol-Myers Squibb Company Information
- 13.4.2 Bristol-Myers Squibb Blood Cancer Treatments Product Portfolios and Specifications
- 13.4.3 Bristol-Myers Squibb Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.4.4 Bristol-Myers Squibb Main Business Overview
- 13.4.5 Bristol-Myers Squibb Latest Developments
- 13.5 Johnson & Johnson
 - 13.5.1 Johnson & Johnson Company Information
 - 13.5.2 Johnson & Johnson Blood Cancer Treatments Product Portfolios and Specifications
 - 13.5.3 Johnson & Johnson Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Johnson & Johnson Main Business Overview
 - 13.5.5 Johnson & Johnson Latest Developments
- 13.6 Merck & Co.
 - 13.6.1 Merck & Co. Company Information
 - 13.6.2 Merck & Co. Blood Cancer Treatments Product Portfolios and Specifications
 - 13.6.3 Merck & Co. Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Merck & Co. Main Business Overview
 - 13.6.5 Merck & Co. Latest Developments
- 13.7 AstraZeneca
 - 13.7.1 AstraZeneca Company Information
 - 13.7.2 AstraZeneca Blood Cancer Treatments Product Portfolios and Specifications
 - 13.7.3 AstraZeneca Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 AstraZeneca Main Business Overview
 - 13.7.5 AstraZeneca Latest Developments
- 13.8 Pfizer
 - 13.8.1 Pfizer Company Information
 - 13.8.2 Pfizer Blood Cancer Treatments Product Portfolios and Specifications
 - 13.8.3 Pfizer Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Pfizer Main Business Overview
 - 13.8.5 Pfizer Latest Developments
- 13.9 Amgen
 - 13.9.1 Amgen Company Information
 - 13.9.2 Amgen Blood Cancer Treatments Product Portfolios and Specifications

13.9.3 Amgen Blood Cancer Treatments Sales, Revenue, Price and Gross Margin
(2021-2026)

13.9.4 Amgen Main Business Overview

13.9.5 Amgen Latest Developments

13.10 Eli Lilly

13.10.1 Eli Lilly Company Information

13.10.2 Eli Lilly Blood Cancer Treatments Product Portfolios and Specifications

13.10.3 Eli Lilly Blood Cancer Treatments Sales, Revenue, Price and Gross Margin
(2021-2026)

13.10.4 Eli Lilly Main Business Overview

13.10.5 Eli Lilly Latest Developments

13.11 AbbVie

13.11.1 AbbVie Company Information

13.11.2 AbbVie Blood Cancer Treatments Product Portfolios and Specifications

13.11.3 AbbVie Blood Cancer Treatments Sales, Revenue, Price and Gross Margin
(2021-2026)

13.11.4 AbbVie Main Business Overview

13.11.5 AbbVie Latest Developments

13.12 Takeda

13.12.1 Takeda Company Information

13.12.2 Takeda Blood Cancer Treatments Product Portfolios and Specifications

13.12.3 Takeda Blood Cancer Treatments Sales, Revenue, Price and Gross Margin
(2021-2026)

13.12.4 Takeda Main Business Overview

13.12.5 Takeda Latest Developments

13.13 Astellas

13.13.1 Astellas Company Information

13.13.2 Astellas Blood Cancer Treatments Product Portfolios and Specifications

13.13.3 Astellas Blood Cancer Treatments Sales, Revenue, Price and Gross Margin
(2021-2026)

13.13.4 Astellas Main Business Overview

13.13.5 Astellas Latest Developments

13.14 Ipsen

13.14.1 Ipsen Company Information

13.14.2 Ipsen Blood Cancer Treatments Product Portfolios and Specifications

13.14.3 Ipsen Blood Cancer Treatments Sales, Revenue, Price and Gross Margin
(2021-2026)

13.14.4 Ipsen Main Business Overview

13.14.5 Ipsen Latest Developments

13.15 Sanofi

13.15.1 Sanofi Company Information

13.15.2 Sanofi Blood Cancer Treatments Product Portfolios and Specifications

13.15.3 Sanofi Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Sanofi Main Business Overview

13.15.5 Sanofi Latest Developments

13.16 Bayer

13.16.1 Bayer Company Information

13.16.2 Bayer Blood Cancer Treatments Product Portfolios and Specifications

13.16.3 Bayer Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Bayer Main Business Overview

13.16.5 Bayer Latest Developments

13.17 Biogen Idec

13.17.1 Biogen Idec Company Information

13.17.2 Biogen Idec Blood Cancer Treatments Product Portfolios and Specifications

13.17.3 Biogen Idec Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Biogen Idec Main Business Overview

13.17.5 Biogen Idec Latest Developments

13.18 Teva

13.18.1 Teva Company Information

13.18.2 Teva Blood Cancer Treatments Product Portfolios and Specifications

13.18.3 Teva Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Teva Main Business Overview

13.18.5 Teva Latest Developments

13.19 Otsuka

13.19.1 Otsuka Company Information

13.19.2 Otsuka Blood Cancer Treatments Product Portfolios and Specifications

13.19.3 Otsuka Blood Cancer Treatments Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 Otsuka Main Business Overview

13.19.5 Otsuka Latest Developments

13.20 Eisai

13.20.1 Eisai Company Information

13.20.2 Eisai Blood Cancer Treatments Product Portfolios and Specifications

13.20.3 Eisai Blood Cancer Treatments Sales, Revenue, Price and Gross Margin

(2021-2026)

13.20.4 Eisai Main Business Overview

13.20.5 Eisai Latest Developments

13.21 Merck KGaA

13.21.1 Merck KGaA Company Information

13.21.2 Merck KGaA Blood Cancer Treatments Product Portfolios and Specifications

13.21.3 Merck KGaA Blood Cancer Treatments Sales, Revenue, Price and Gross

Margin (2021-2026)

13.21.4 Merck KGaA Main Business Overview

13.21.5 Merck KGaA Latest Developments

13.22 Gilead Sciences

13.22.1 Gilead Sciences Company Information

13.22.2 Gilead Sciences Blood Cancer Treatments Product Portfolios and Specifications

13.22.3 Gilead Sciences Blood Cancer Treatments Sales, Revenue, Price and Gross

Margin (2021-2026)

13.22.4 Gilead Sciences Main Business Overview

13.22.5 Gilead Sciences Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Blood Cancer Treatments Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Blood Cancer Treatments Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Chemotherapy

Table 4. Major Players of Targeted Therapy

Table 5. Major Players of Immunotherapy (Biologic Therapy)

Table 6. Major Players of Hormonal Therapy

Table 7. Major Players of Others

Table 8. Global Blood Cancer Treatments Sales by Type (2021-2026) & (K Units)

Table 9. Global Blood Cancer Treatments Sales Market Share by Type (2021-2026)

Table 10. Global Blood Cancer Treatments Revenue by Type (2021-2026) & (\$ million)

Table 11. Global Blood Cancer Treatments Revenue Market Share by Type (2021-2026)

Table 12. Global Blood Cancer Treatments Sale Price by Type (2021-2026) & (US\$/Unit)

Table 13. Global Blood Cancer Treatments Sale by Application (2021-2026) & (K Units)

Table 14. Global Blood Cancer Treatments Sale Market Share by Application (2021-2026)

Table 15. Global Blood Cancer Treatments Revenue by Application (2021-2026) & (\$ million)

Table 16. Global Blood Cancer Treatments Revenue Market Share by Application (2021-2026)

Table 17. Global Blood Cancer Treatments Sale Price by Application (2021-2026) & (US\$/Unit)

Table 18. Global Blood Cancer Treatments Sales by Company (2021-2026) & (K Units)

Table 19. Global Blood Cancer Treatments Sales Market Share by Company (2021-2026)

Table 20. Global Blood Cancer Treatments Revenue by Company (2021-2026) & (\$ millions)

Table 21. Global Blood Cancer Treatments Revenue Market Share by Company (2021-2026)

Table 22. Global Blood Cancer Treatments Sale Price by Company (2021-2026) & (US\$/Unit)

Table 23. Key Manufacturers Blood Cancer Treatments Producing Area Distribution and

Sales Area

Table 24. Players Blood Cancer Treatments Products Offered

Table 25. Blood Cancer Treatments Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 26. New Products and Potential Entrants

Table 27. Market M&A Activity & Strategy

Table 28. Global Blood Cancer Treatments Sales by Geographic Region (2021-2026) & (K Units)

Table 29. Global Blood Cancer Treatments Sales Market Share Geographic Region (2021-2026)

Table 30. Global Blood Cancer Treatments Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 31. Global Blood Cancer Treatments Revenue Market Share by Geographic Region (2021-2026)

Table 32. Global Blood Cancer Treatments Sales by Country/Region (2021-2026) & (K Units)

Table 33. Global Blood Cancer Treatments Sales Market Share by Country/Region (2021-2026)

Table 34. Global Blood Cancer Treatments Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global Blood Cancer Treatments Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas Blood Cancer Treatments Sales by Country (2021-2026) & (K Units)

Table 37. Americas Blood Cancer Treatments Sales Market Share by Country (2021-2026)

Table 38. Americas Blood Cancer Treatments Revenue by Country (2021-2026) & (\$ millions)

Table 39. Americas Blood Cancer Treatments Sales by Type (2021-2026) & (K Units)

Table 40. Americas Blood Cancer Treatments Sales by Application (2021-2026) & (K Units)

Table 41. APAC Blood Cancer Treatments Sales by Region (2021-2026) & (K Units)

Table 42. APAC Blood Cancer Treatments Sales Market Share by Region (2021-2026)

Table 43. APAC Blood Cancer Treatments Revenue by Region (2021-2026) & (\$ millions)

Table 44. APAC Blood Cancer Treatments Sales by Type (2021-2026) & (K Units)

Table 45. APAC Blood Cancer Treatments Sales by Application (2021-2026) & (K Units)

Table 46. Europe Blood Cancer Treatments Sales by Country (2021-2026) & (K Units)

Table 47. Europe Blood Cancer Treatments Revenue by Country (2021-2026) & (\$

millions)

Table 48. Europe Blood Cancer Treatments Sales by Type (2021-2026) & (K Units)

Table 49. Europe Blood Cancer Treatments Sales by Application (2021-2026) & (K Units)

Table 50. Middle East & Africa Blood Cancer Treatments Sales by Country (2021-2026) & (K Units)

Table 51. Middle East & Africa Blood Cancer Treatments Revenue Market Share by Country (2021-2026)

Table 52. Middle East & Africa Blood Cancer Treatments Sales by Type (2021-2026) & (K Units)

Table 53. Middle East & Africa Blood Cancer Treatments Sales by Application (2021-2026) & (K Units)

Table 54. Key Market Drivers & Growth Opportunities of Blood Cancer Treatments

Table 55. Key Market Challenges & Risks of Blood Cancer Treatments

Table 56. Key Industry Trends of Blood Cancer Treatments

Table 57. Blood Cancer Treatments Raw Material

Table 58. Key Suppliers of Raw Materials

Table 59. Blood Cancer Treatments Distributors List

Table 60. Blood Cancer Treatments Customer List

Table 61. Global Blood Cancer Treatments Sales Forecast by Region (2027-2032) & (K Units)

Table 62. Global Blood Cancer Treatments Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 63. Americas Blood Cancer Treatments Sales Forecast by Country (2027-2032) & (K Units)

Table 64. Americas Blood Cancer Treatments Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 65. APAC Blood Cancer Treatments Sales Forecast by Region (2027-2032) & (K Units)

Table 66. APAC Blood Cancer Treatments Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 67. Europe Blood Cancer Treatments Sales Forecast by Country (2027-2032) & (K Units)

Table 68. Europe Blood Cancer Treatments Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Middle East & Africa Blood Cancer Treatments Sales Forecast by Country (2027-2032) & (K Units)

Table 70. Middle East & Africa Blood Cancer Treatments Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 71. Global Blood Cancer Treatments Sales Forecast by Type (2027-2032) & (K Units)

Table 72. Global Blood Cancer Treatments Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 73. Global Blood Cancer Treatments Sales Forecast by Application (2027-2032) & (K Units)

Table 74. Global Blood Cancer Treatments Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 75. Roche Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 76. Roche Blood Cancer Treatments Product Portfolios and Specifications

Table 77. Roche Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 78. Roche Main Business

Table 79. Roche Latest Developments

Table 80. Celgene Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 81. Celgene Blood Cancer Treatments Product Portfolios and Specifications

Table 82. Celgene Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 83. Celgene Main Business

Table 84. Celgene Latest Developments

Table 85. Novartis Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 86. Novartis Blood Cancer Treatments Product Portfolios and Specifications

Table 87. Novartis Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 88. Novartis Main Business

Table 89. Novartis Latest Developments

Table 90. Bristol-Myers Squibb Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 91. Bristol-Myers Squibb Blood Cancer Treatments Product Portfolios and Specifications

Table 92. Bristol-Myers Squibb Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 93. Bristol-Myers Squibb Main Business

Table 94. Bristol-Myers Squibb Latest Developments

Table 95. Johnson & Johnson Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 96. Johnson & Johnson Blood Cancer Treatments Product Portfolios and Specifications

Table 97. Johnson & Johnson Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 98. Johnson & Johnson Main Business

Table 99. Johnson & Johnson Latest Developments

Table 100. Merck & Co. Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 101. Merck & Co. Blood Cancer Treatments Product Portfolios and Specifications

Table 102. Merck & Co. Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 103. Merck & Co. Main Business

Table 104. Merck & Co. Latest Developments

Table 105. AstraZeneca Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 106. AstraZeneca Blood Cancer Treatments Product Portfolios and Specifications

Table 107. AstraZeneca Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 108. AstraZeneca Main Business

Table 109. AstraZeneca Latest Developments

Table 110. Pfizer Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 111. Pfizer Blood Cancer Treatments Product Portfolios and Specifications

Table 112. Pfizer Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 113. Pfizer Main Business

Table 114. Pfizer Latest Developments

Table 115. Amgen Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 116. Amgen Blood Cancer Treatments Product Portfolios and Specifications

Table 117. Amgen Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 118. Amgen Main Business

Table 119. Amgen Latest Developments

Table 120. Eli Lilly Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 121. Eli Lilly Blood Cancer Treatments Product Portfolios and Specifications

Table 122. Eli Lilly Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 123. Eli Lilly Main Business

Table 124. Eli Lilly Latest Developments

Table 125. AbbVie Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 126. AbbVie Blood Cancer Treatments Product Portfolios and Specifications

Table 127. AbbVie Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 128. AbbVie Main Business

Table 129. AbbVie Latest Developments

Table 130. Takeda Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 131. Takeda Blood Cancer Treatments Product Portfolios and Specifications

Table 132. Takeda Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 133. Takeda Main Business

Table 134. Takeda Latest Developments

Table 135. Astellas Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 136. Astellas Blood Cancer Treatments Product Portfolios and Specifications

Table 137. Astellas Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 138. Astellas Main Business

Table 139. Astellas Latest Developments

Table 140. Ipsen Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 141. Ipsen Blood Cancer Treatments Product Portfolios and Specifications

Table 142. Ipsen Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 143. Ipsen Main Business

Table 144. Ipsen Latest Developments

Table 145. Sanofi Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 146. Sanofi Blood Cancer Treatments Product Portfolios and Specifications

Table 147. Sanofi Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 148. Sanofi Main Business

Table 149. Sanofi Latest Developments

Table 150. Bayer Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 151. Bayer Blood Cancer Treatments Product Portfolios and Specifications

Table 152. Bayer Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 153. Bayer Main Business

Table 154. Bayer Latest Developments

Table 155. Biogen Idec Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 156. Biogen Idec Blood Cancer Treatments Product Portfolios and Specifications

Table 157. Biogen Idec Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 158. Biogen Idec Main Business

Table 159. Biogen Idec Latest Developments

Table 160. Teva Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 161. Teva Blood Cancer Treatments Product Portfolios and Specifications

Table 162. Teva Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 163. Teva Main Business

Table 164. Teva Latest Developments

Table 165. Otsuka Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 166. Otsuka Blood Cancer Treatments Product Portfolios and Specifications

Table 167. Otsuka Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 168. Otsuka Main Business

Table 169. Otsuka Latest Developments

Table 170. Eisai Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 171. Eisai Blood Cancer Treatments Product Portfolios and Specifications

Table 172. Eisai Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 173. Eisai Main Business

Table 174. Eisai Latest Developments

Table 175. Merck KGaA Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 176. Merck KGaA Blood Cancer Treatments Product Portfolios and Specifications

Table 177. Merck KGaA Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 178. Merck KGaA Main Business

Table 179. Merck KGaA Latest Developments

Table 180. Gilead Sciences Basic Information, Blood Cancer Treatments Manufacturing Base, Sales Area and Its Competitors

Table 181. Gilead Sciences Blood Cancer Treatments Product Portfolios and Specifications

Table 182. Gilead Sciences Blood Cancer Treatments Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 183. Gilead Sciences Main Business

Table 184. Gilead Sciences Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Blood Cancer Treatments
- Figure 2. Blood Cancer Treatments Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Blood Cancer Treatments Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Blood Cancer Treatments Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Blood Cancer Treatments Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Blood Cancer Treatments Sales Market Share by Country/Region (2025)
- Figure 10. Blood Cancer Treatments Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Chemotherapy
- Figure 12. Product Picture of Targeted Therapy
- Figure 13. Product Picture of Immunotherapy (Biologic Therapy)
- Figure 14. Product Picture of Hormonal Therapy
- Figure 15. Product Picture of Others
- Figure 16. Global Blood Cancer Treatments Sales Market Share by Type in 2026
- Figure 17. Global Blood Cancer Treatments Revenue Market Share by Type (2021-2026)
- Figure 18. Blood Cancer Treatments Consumed in Leukemia
- Figure 19. Global Blood Cancer Treatments Market: Leukemia (2021-2026) & (K Units)
- Figure 20. Blood Cancer Treatments Consumed in lymphoma
- Figure 21. Global Blood Cancer Treatments Market: lymphoma (2021-2026) & (K Units)
- Figure 22. Blood Cancer Treatments Consumed in Myeloma
- Figure 23. Global Blood Cancer Treatments Market: Myeloma (2021-2026) & (K Units)
- Figure 24. Blood Cancer Treatments Consumed in Others
- Figure 25. Global Blood Cancer Treatments Market: Others (2021-2026) & (K Units)
- Figure 26. Global Blood Cancer Treatments Sale Market Share by Application (2025)
- Figure 27. Global Blood Cancer Treatments Revenue Market Share by Application in 2026
- Figure 28. Blood Cancer Treatments Sales by Company in 2026 (K Units)
- Figure 29. Global Blood Cancer Treatments Sales Market Share by Company in 2026
- Figure 30. Blood Cancer Treatments Revenue by Company in 2026 (\$ millions)

Figure 31. Global Blood Cancer Treatments Revenue Market Share by Company in 2026

Figure 32. Global Blood Cancer Treatments Sales Market Share by Geographic Region (2021-2026)

Figure 33. Global Blood Cancer Treatments Revenue Market Share by Geographic Region in 2026

Figure 34. Americas Blood Cancer Treatments Sales 2021-2026 (K Units)

Figure 35. Americas Blood Cancer Treatments Revenue 2021-2026 (\$ millions)

Figure 36. APAC Blood Cancer Treatments Sales 2021-2026 (K Units)

Figure 37. APAC Blood Cancer Treatments Revenue 2021-2026 (\$ millions)

Figure 38. Europe Blood Cancer Treatments Sales 2021-2026 (K Units)

Figure 39. Europe Blood Cancer Treatments Revenue 2021-2026 (\$ millions)

Figure 40. Middle East & Africa Blood Cancer Treatments Sales 2021-2026 (K Units)

Figure 41. Middle East & Africa Blood Cancer Treatments Revenue 2021-2026 (\$ millions)

Figure 42. Americas Blood Cancer Treatments Sales Market Share by Country in 2026

Figure 43. Americas Blood Cancer Treatments Revenue Market Share by Country (2021-2026)

Figure 44. Americas Blood Cancer Treatments Sales Market Share by Type (2021-2026)

Figure 45. Americas Blood Cancer Treatments Sales Market Share by Application (2021-2026)

Figure 46. United States Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 47. Canada Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 48. Mexico Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 49. Brazil Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 50. APAC Blood Cancer Treatments Sales Market Share by Region in 2026

Figure 51. APAC Blood Cancer Treatments Revenue Market Share by Region (2021-2026)

Figure 52. APAC Blood Cancer Treatments Sales Market Share by Type (2021-2026)

Figure 53. APAC Blood Cancer Treatments Sales Market Share by Application (2021-2026)

Figure 54. China Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 55. Japan Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 56. South Korea Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 57. Southeast Asia Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 58. India Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 59. Australia Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 60. China Taiwan Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 61. Europe Blood Cancer Treatments Sales Market Share by Country in 2026

Figure 62. Europe Blood Cancer Treatments Revenue Market Share by Country (2021-2026)

Figure 63. Europe Blood Cancer Treatments Sales Market Share by Type (2021-2026)

Figure 64. Europe Blood Cancer Treatments Sales Market Share by Application (2021-2026)

Figure 65. Germany Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 66. France Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 67. UK Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 68. Italy Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 69. Russia Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 70. Middle East & Africa Blood Cancer Treatments Sales Market Share by Country (2021-2026)

Figure 71. Middle East & Africa Blood Cancer Treatments Sales Market Share by Type (2021-2026)

Figure 72. Middle East & Africa Blood Cancer Treatments Sales Market Share by Application (2021-2026)

Figure 73. Egypt Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 74. South Africa Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 75. Israel Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 76. Turkey Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 77. GCC Countries Blood Cancer Treatments Revenue Growth 2021-2026 (\$ millions)

Figure 78. Manufacturing Cost Structure Analysis of Blood Cancer Treatments in 2026

Figure 79. Manufacturing Process Analysis of Blood Cancer Treatments

Figure 80. Industry Chain Structure of Blood Cancer Treatments

Figure 81. Channels of Distribution

Figure 82. Global Blood Cancer Treatments Sales Market Forecast by Region (2027-2032)

Figure 83. Global Blood Cancer Treatments Revenue Market Share Forecast by Region (2027-2032)

Figure 84. Global Blood Cancer Treatments Sales Market Share Forecast by Type (2027-2032)

Figure 85. Global Blood Cancer Treatments Revenue Market Share Forecast by Type

(2027-2032)

Figure 86. Global Blood Cancer Treatments Sales Market Share Forecast by
Application (2027-2032)

Figure 87. Global Blood Cancer Treatments Revenue Market Share Forecast by
Application (2027-2032)

I would like to order

Product name: Global Blood Cancer Treatments Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GEE76FEA5386EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEE76FEA5386EN.html>